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Summary
P2X7 receptors function as ATP-gated cation channels but also interact with other proteins as part of a larger signalling complex to mediate a
variety of downstream responses that are dependent upon the cell type in which they are expressed. Receptor-mediated membrane
permeabilization to large molecules precedes the induction of cell death, but remains poorly understood. The mechanisms that underlie
differential sensitivity to NAD are also unknown. By studying alternative variants of the mouse P2X7 receptor we show that sensitivity to
NAD is mediated through the P2X7k variant, which has a much more restricted distribution than the P2X7a receptor, but is expressed in T
lymphocytes. The altered N-terminus and TM1 of the P2X7k receptor enhances the stability of the active state of this variant compared with
P2X7a, thereby increasing the efficacy of NAD-dependent ADP ribosylation as measured by ethidium uptake, a rise in intracellular Ca2+ and
the activation of inward currents. Co-expression of P2X7k and P2X7a receptors reduced NAD sensitivity. P2X7k-receptor-mediated
ethidium uptake was also triggered by much lower BzATP concentrations and was insensitive to the P451L single nucleotide polymorphism.
P2X7k-receptor-mediated ethidium uptake occurred independently of pannexin-1 suggesting a pathway intrinsic to the receptor. Only for the
P2X7aL451 receptor could we resolve a component of dye uptake dependent upon pannexin-1. Signalling occurred downstream of the
activation of caspases rather than involving direct cross talk between the channels. However, an in situ proximity assay showed close
association between P2X7 receptors and pannexin-1, which would facilitate ATP efflux through pannexin-1 acting in an autocrine manner.
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Introduction
P2X7 receptors are predominantly immune and epithelial cell
receptors which mediate many diverse responses that include the
processing and release of proinflammatory cytokines, the
phagocytosis and subsequent killing of pathogens, increased
cell proliferation and survival and cell death by apoptosis and
necrosis (Adinolfi et al., 2005; Brough et al., 2002; Cabrini et al.,
2005; Chen and Brosnan, 2006; Di Virgilio et al., 2001; Guerra
et al., 2003; Mackenzie et al., 2005; North, 2002; Placido et al.,
2006). They have low affinity for extracellular ATP compared to
the other members of the P2X family (North, 2002) and the levels
required to maximally stimulate the receptor are more likely to
occur where there is pathology or injury; thus it has been
postulated that this receptor mediates the actions of ATP as a
danger signal. The role of this receptor in diseases that involve
chronic inflammation or cancer makes it a potentially useful
therapeutic target, and antagonists have been developed and
tested for clinical trials (Chessell et al., 2005; Dardano et al.,
2009; Donnelly-Roberts and Jarvis, 2007; Feng et al., 2006a;
Wiley et al., 2002).
How the expression and activation of P2X7 receptors triggers
such a diversity of responses is not well understood. Similar to other
P2X receptors, when activated they mediate the rapid flux of mono-
and divalent cation, and the resulting loss of K+ from the cell and
rise in Ca2+ are both involved in triggering downstream responses
(North, 2002). What distinguishes the P2X7 receptor from the other
members of this family is its very long cytoplasmic C-terminal tail,
which is important for targeting of this receptor to the plasma
membrane, its function and for interactions with other proteins
(Denlinger et al., 2001; Kim et al., 2001; North, 2002; Nuttle and
Dubyak, 1994; Smart et al., 2003; Wilson et al., 2002). This region
confers upon the receptor additional unique functions that
distinguish it from the other P2X subtypes. One of the most
extensively studied is membrane permeabilization to relatively large
molecules up to 900Da in size that occurs within seconds of
activating the P2X7 receptor and is routinely assayed by the uptake
of fluorescent dyes such as ethidium (North, 2002; Nuttle and
Dubyak, 1994). This process occurs on a similar time scale to
receptor-triggered externalization of phosphatidylserine (PS) to the
plasma membrane outer leaflet and precedes membrane blebbing
(Mackenzie et al., 2005; Pfeiffer et al., 2004; Verhoef et al., 2003).
These responses are associated with P2X7 receptor dependent cell
death, and single nucleotide polymorphisms (SNPs) that inhibit the
large pore formation, similarly inhibit cell death. One such SNP is
P451L; this substitution occurs naturally in the C57BL/6 strain of
mice and reduces the rate of dye uptake but does not compromise
agonist-evoked whole-cell currents (Adriouch et al., 2002; Le Stunff
et al., 2004).
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The P2X7 receptor is thought to exist as part of a larger
signalling complex, and several proteins have been identified as
interacting with it. These include cytoskeletal elements and other
ion channels including the P2X4 receptor and pannexin-1
(Boumechache et al., 2009; Denlinger et al., 2001; Gu et al.,
2009; Iglesias et al., 2008; Kim et al., 2001; Pelegrin and
Surprenant, 2006). The interaction between P2X7 and pannexin-1
(PANX1) was proposed to play an important role in mediating
membrane permeabilization to large molecules with the suggestion
that PANX1 forms the large pore rather than it being intrinsic to
the P2X7 receptor itself. Overexpression of PANX1 increased the
rate of P2X7 receptor-mediated dye uptake whereas knock down
of PANX1 function either by siRNA or the use of pharmacological
inhibitors reduced dye uptake (Iglesias et al., 2008; Locovei et al.,
2006; Pelegrin and Surprenant, 2006). PANX1 channels pass
strongly outwardly rectifying currents, provide a route for efflux of
ATP and are blocked by carbenoxolone (CBX) and a mimetic
peptide (10panx1) (Scemes et al., 2009). They are activated by
caspases, which recognize a site between residues 376 and 379 and
cleave the C-terminus (Chekeni et al., 2010). Hypotonic shock is
also reported to activate the channel suggesting that it might be
mechano-sensitive (Locovei et al., 2006; Ransford et al., 2009).
The proposal that PANX1 is the principal dye-uptake pathway
triggered by the activation of the P2X7 receptor remains
controversial. There is evidence for two distinct pathways, one
for anions and the other for cations, with inhibitors of PANX1
blocking neither pathway (Cankurtaran-Sayar et al., 2009;
Schachter et al., 2008). PANX1-mediated currents were shown
to be inhibited by ATP and 39-O-(4-benzoyl)benzoyl ATP
(BzATP) at concentrations commonly used to activate P2X7
receptors (Ma et al., 2009; Qiu and Dahl, 2009). Finally, recent
experiments using bone marrow derived macrophages from
PANX1 deficient mice have shown that dye uptake in these cells
is not reduced compared to wild-type cells, suggesting that
PANX1 is not required for P2X7 receptor-mediated dye uptake
(Qu et al., 2011). An alternative hypothesis is that dye uptake is
intrinsic to the P2X7 receptor and in support of this idea is the
evidence to indicate that the pore of P2X7, and other P2X
subtypes, can dilate during prolonged agonist application.
Although initially selective for small mono and divalent
cations, over a period of seconds, the permeation of larger
cations such as NMDG+ is permitted (Eickhorst et al., 2002;
Khakh et al., 1999; Virginio et al., 1999; Yan et al., 2008).
The cellular responses triggered by the P2X7 receptor will
depend upon the structure of the receptor itself in addition to the
expression of other proteins with which it can interact. Several
splice variants and SNPs have been identified for both the human
and rodent isoforms, some of which are linked with disease
(Adriouch et al., 2002; Cabrini et al., 2005; Cheewatrakoolpong
et al., 2005; Dardano et al., 2009; Feng et al., 2006a; Gu et al.,
2001; Nicke et al., 2009). For the human receptor, a prevalent C-
terminal truncated splice variant, P2X7B, has been described
which fails to trigger membrane permeabilization to large
molecules but still stimulates the rate of cell growth (Adinolfi
et al., 2010; Cheewatrakoolpong et al., 2005). We have described
similar C-terminal truncated variants of the mouse isoform
(Masin et al., 2012), plus a novel rodent splice variant, P2X7k,
which utilizes an alternative exon 1 encoding the N-terminus and
part of the TM1. The rat P2X7k receptor is activated by lower
agonist concentrations than the P2X7a variant and shows faster
kinetics of membrane permeabilization and blebbing; properties
that are more consistent with the cell death promoting actions of
P2X7 receptor signalling (Nicke et al., 2009).
Variation in P2X7 receptor structure could explain the
differential sensitivity to agonist displayed by receptors
expressed in different cell types. P2X7 receptors in mouse T-
lymphocytes are activated by nicotinamide adenine dinucleotide
(NAD) in addition to ATP, whereas macrophage P2X7 receptors
are not (Hong et al., 2009; Seman et al., 2003). NAD is a
substrate for ADP ribosylation of the receptor, a reaction that is
catalyzed by ART2.2, a GPI-anchored ADP-ribosyltransferase
(Adriouch et al., 2008). Micromolar levels of NAD triggers
phosphatidylserine flip and ultimately cell death of T-
lymphocytes (Seman et al., 2003). In contrast, macrophages
show no response despite expressing ART2.1 (Hong et al., 2009).
In this study we investigated the contribution of the P2X7a and
P2X7k receptor variants to the diversity of P2X7 receptor
signalling and also took advantage of the differences in their
properties to probe the nature of the functional coupling between
P2X7 and PANX1 and the role PANX1 plays in receptor-
mediated membrane permeabilization. We show that the P2X7k
receptor variant is responsible for NAD-dependent gating of the
T-cell receptors and provide evidence for the formation of
P2X7a/k heteromers with reduced sensitivity to agonist. Rapid
dye uptake triggered by P2X7k receptor activation is independent
of PANX1 and only when dye uptake is compromised in the
P2X7a variant can a PANX1 dependent component be resolved,
downstream of caspase activation.
Results
Enhanced sensitivity of the P2X7k receptor and tolerance
of the L451 SNP
We compared the functional properties of the mouse P2X7a and
k receptor variants with the expectation that the enhanced activity
of the k variant that was previously shown for the rat isoform
(Nicke et al., 2009) would also be seen when comparing the
mouse receptors. We did this using the two backgrounds, P451
and L451, to test whether or not or not leucine at position 451
impairs dye uptake in the more active k variant as was shown for
the P2X7a receptor (Adriouch et al., 2002). Whole-cell currents
measured in HEK cells heterologously expressing the two
receptors indicated that BzATP was more potent at the P2X7k
than the P2X7a receptor (Fig. 1A). Concentration–response
relationships were generated by normalizing currents for each
cell to the response to 1 mM and 100 mM BzATP for the P2X7a
and P2X7k receptors respectively. The EC50 values were
,10-fold lower for the P2X7k versus P2X7a receptor but the
curves overlapped for the L451 and P451 forms. Comparing peak
current densities, the responses evoked by 300 mM BzATP were
considerably larger for the P2X7k receptor compared to the
P2X7a receptor (Fig. 1B), but when responses to doses close to
the EC50 values and near maximal were compared, there was no
significant difference in the peak current densities between all
4 forms of the receptor. Thus, functional plasma membrane
expression of the receptors appears to be similar.
Membrane permeabilization to fluorescent dyes was measured
by confocal microscopy. For the P2X7a receptor, L451 reduced
the rate of BzATP-stimulated ethidium uptake compared to P451,
as shown previously (Adriouch et al., 2002), whereas for the
P2X7k receptor there was no compromise in ethidium uptake for
L451 compared to P451 (Fig. 1C). Concentration–response
curves were generated by subtracting the constitutive rate of
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ethidium uptake from the rate of uptake 15–35 s post application
of BzATP, and normalizing to the response to 100 mM BzATP at
the P2X7kP receptor (Fig. 1D). For the P2X7k receptor the EC50
values were again at least tenfold lower than for the P2X7a
receptor and the maximal response was also significantly higher
(P,0.01). The EC50 values were reduced compared to the current
measurements because experiments were carried out in the low
divalent extracellular solution. Interpreting these results, for the
P2X7a receptor, the selective effect of the P451L mutation on
dye uptake indicates that there are at least two distinct active
states, one that permits the flux of small cations and the other that
also, directly or indirectly, permits influx of the cationic dye,
ethidium. The permissive state for dye influx does not appear to
be a higher conducting state for the major charge carrying ion,
Na+. For the P2X7k receptors both active states are more stable
and not compromised by the leucine at position 451.
P2X7k receptor is expressed in splenic T lymphocytes and
mediates the effects of NAD
Previously, we showed that the P2X7k receptor is expressed in
the spleen of the Glaxo P2X72/2 mice but not in bone marrow
derived macrophages from these mice, nor in many other tissues
(Boumechache et al., 2009; Nicke et al., 2009). To determine
whether or not T lymphocytes in the spleen express this receptor
we isolated them from freshly dissociated tissue and probed for
expression of P2X7 using a C-terminal antibody. A band of the
expected size was detected in T-lymphocytes from both WT
and P2X72/2 mice (Fig. 2A). Although we cannot distinguish
between P2X7a and P2X7k receptors in the WT tissue,
expression of P2X7a receptors is abolished in the P2X72/2
mice and therefore we are confident that the receptor detected
here represents P2X7k.
T-cell P2X7 receptors can be activated by NAD via ADP
ribosylation catalyzed by ART2 (Seman et al., 2003).
Macrophage receptors and P2X7a receptors co-expressed with
ART2.2 in HEK cells are insensitive to NAD (Hong et al., 2009).
To investigate the possibility that P2X7k receptors mediates
NAD sensitivity we co-expressed P2X7kP451 with ART2.2 in
HEK cells and measured ethidium uptake over a range of NAD
concentrations up to 300 mM. Concentrations of NAD of 10 mM
and above stimulated ethidium uptake compared to the rate
observed in the absence of NAD and the effect was dependent
upon the co-expression of ART2.2 (Fig. 2B). The potentiation by
NAD was all-or-nothing over the time scale of these experiments
Fig. 1. The P2X7k receptor variant is activated by
lower agonist concentrations and mediates dye
uptake insensitive to the P451L SNP. (A) Whole-cell
patch-clamp recordings from HEK cells expressing
either the P2X7k or P2X7a receptor, with P451.
Currents were evoked by a 5 s application of BzATP at
a holding potential of 260 mV. To generate
concentration–response curves, currents in each cell
were normalized to the response to either 1 mM BzATP,
for P2X7a, or 100 mM BzATP, for the P2X7k receptor.
EC50 values: P2X7aL, 1.1 mM; P2X7aP, 1.0 mM;
P2X7kL, 125 mM; P2X7kP, 105 mM (n54–6 cells).
(B) The current densities evoked by 300 mM BzATP
show the significantly larger responses at the P2X7k
versus P2X7a receptors (n54–6 cells; *P,0.01).
Comparing responses to doses close to the EC50 values
and near maximal, the current densities were very
similar for all four forms of the receptor.
(C) Representative time courses of the increase in
fluorescence, as measured by confocal microscopy, in
HEK cells expressing either P2X7a or P2X7k receptors
following application of BzATP at the concentrations
stated, in the presence of ethidium bromide (20 mM).
The P451L SNP reduced dye uptake mediated by P2X7a
but not P2X7k receptors. (D) A comparison of the rate
of ethidium uptake mediated by P2X7aP and P2X7kP
receptors. Concentration–response curves for the rate of
increase in fluorescence 15–35 s following BzATP
application, normalized to the rate mediated by P2X7kP
in response to 100 mM BzATP, measured on the same
day. Recordings were made in a low divalent
extracellular solution. EC50 values: P2X7aL, 147 mM;
P2X7aP, 100 mM; P2X7kL 9.93 mM; P2X7kP, 10.2 mM
(n53 with 60 cells analyzed per experiment).
Comparing the maximal rate of dye uptake mediated by
the receptors, there was a significant difference between
P2X7k and P2X7a receptors (*P,0.01) and between
P2X7aP and P2X7aL receptors (*P,0.01).
Journal of Cell Science 125 (16)3778
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Fig. 2. P2X7k receptor is expressed in splenic T lymphocytes and mediates dye uptake in response to NAD-stimulated ADP ribosylation. (A) Western blot
of T lymphocytes isolated from the spleen of WT mice and Glaxo P2X72/2 mice. Two dilutions from each sample were run and P2X7 was detected using a C-
terminal anti-P2X7 antibody that detects both P2X7a and P2X7k receptors. (B) NAD-stimulated increase in ethidium fluorescence in cells co-expressing the
P2X7kP(451) receptor and ART2.2 or P2X7kP alone. Ethidium bromide was added at 60 s and NAD at 120 s. The rate of increase in fluorescence (between 30–
100 s after NAD addition) was significantly greater following application of either 30 mM or 300 mM NAD than in the absence of NAD or in cells that did not co-
express ART2.2 (n580–180 cells; *P,0.01). (C) HEK cells co-expressing P2X7aP receptors and ART2.2 or P2X7aP alone did not respond to NAD (n560–130
cells; P.0.05). (D) For HEK cells co-expressing both P2X7aP and P2X7kP receptors with ART2.2, the rate of increase in fluorescence following application of
30 mM NAD was significantly less than in cells expressing P2X7kP receptors alone (n580–120 cells; P,0.01), but greater than in cells expressing P2X7aP
receptors alone (**n580–130 cells; P,0.05). (E) The concentration–response relationship for BzATP-stimulated ethidium uptake for cells co-expressing P2X7a
and P2X7k receptors, normalized to the response mediated by P2X7k receptors expressed alone (100 mM). Recordings were made in low divalent NES (EC50 5
44 mM; n53; 60 cells per experiment). (F) Western blot analysis using the anti-V5 antibody (left) and anti-HA antibody (right) showed P2X7k–V5 was co-
immunoprecipitated with P2X7a–HA using the anti-HA resin, but only when the receptors were co-expressed.
P2X7R variant reveals new functions 3779
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
with 3 mM having no effect and 10 mM producing a similar
increase in dye uptake as the higher doses. At the P2X7aP451
receptor, NAD over a similar range of concentrations had no
effect on the rate of ethidium uptake either with or without
ART2.2 (Fig. 2C). The co-expression of P2X7a and P2X7k
receptors reduced the response to NAD compared to cells
expressing P2X7k alone, suggesting that these two variants form
heteromers with reduced sensitivity (Fig. 2D). The BzATP
concentration–response curve for the co-expressed receptors
was intermediate between the two receptors expressed
individually (Fig. 2E). These results are consistent with the
observations of Taylor et al., who showed that T cells from the
Glaxo P2X72/2 mice which lacked P2X7a receptors, were more
responsive to ATP than T cells from the WT mice, suggesting
that P2X7k homomeric receptors are more active than the P2X7a/
k heteromers (Taylor et al., 2009).
To further investigate a structural interaction between P2X7a
and P2X7k subunits we differentially tagged them at the C-
terminus with an HA and V5 epitope, respectively. Following
expression in HEK cells, purification was carried out using an
anti-HA resin followed by elution from the resin using an HA
peptide. A band of the expected size for P2X7a-HA was detected
in the immunoprecipitate when P2X7a-HA was expressed alone
or together with P2X7k–V5, whereas P2X7k–V5 was only co-
immunoprecipitated when P2X7a–HA was present (Fig. 2F).
This indicates an interaction between the two subunits consistent
with the formation of heteromeric receptors. The expression of
P2X7a–HA was very similar when expressed alone or together
with P2X7k–V5 although there was a slight decrease in P2X7k–
V5 expression when co-expressed with P2X7a–HA. This would
not, however, explain the shift in the concentration–response
relationship if receptors were functioning independently of one
another.
NAD-dependent ADP ribosylation acts as a partial agonist
at P2X7k receptors
To further characterize the effects of NAD on both P2X7a and k
receptors we measured changes in [Ca2+]i and whole-cell currents
in HEK cells expressing these receptors with ART2.2. Changes in
[Ca2+]i were measured using Fura-Red and confocal microscopy
and in cells expressing P2X7k receptors there was a clear and
sustained increase in [Ca2+]i following application of 30 mM
NAD, whereas there was no response to 300 mM NAD in cells
expressing P2X7a receptors (Fig. 3A). Whole cell patch clamp of
P2X7k receptor expressing cells showed an inward current
evoked by 300 mM NAD with activation kinetics slower than
BzATP-evoked currents and no clear deactivation of the current
following wash out of NAD, over the time period of these
experiments (1–2 min) (Fig. 3B). The amplitude of NAD-evoked
currents was much smaller than currents activated by a near
maximal dose of BzATP. For cells expressing the P2X7a receptor
there was no inward current activated by 300 mM NAD, however
cells exposed to NAD for 5 s gave a smaller response to a
subsequent application of 3 mM MgATP compared to cells only
exposed to ATP (Fig. 3C) and the extent of the inhibition was
dependent upon the concentration of NAD. Similarly, for P2X7k
receptors, prior exposure to 30 mM NAD for 5 s, did not evoke a
current but reduced the response to subsequent application of 1
mM MgATP. The inhibitory effects of NAD on dye uptake
mediated by BzATP were also observed for both receptors
(Fig. 3D). These results suggest that both P2X7a and P2X7k
receptors are ADP ribosylated by application of NAD and that
whilst this acts as a partial agonist at P2X7k receptors, it acts as
an antagonist at P2X7a receptors. These results are broadly
consistent with those of Hong et al., who showed that P2X7a
receptors were ADP ribosylated by NAD application but that this
failed to trigger a rise in [Ca2+]i unless there was a R276K gain of
function mutation in the receptor (Hong et al., 2009).
Differential effects of PANX1 expression on P2X7a- and
P2X7k-receptor-mediated ethidium uptake seen with the
L451 SNP
Both active states of the P2X7k receptor are more stable than for
the P2X7a receptor; BzATP is more potent, ADP ribosylation is
more efficacious and the P451L substitution is no longer
sufficient to impair activity with respect to ethidium uptake. To
investigate the mechanism underlying the rapid ethidium uptake
mediated by P2X7k receptors we looked at the role of PANX1
channels. HEK cells stably overexpressing an HA-tagged version
of the human isoform of PANX1 were generated (PANX1-HEK)
and immunostaining with anti-HA showed expression of the
channel at the plasma membrane whilst western blot analysis of
proteins treated with either N-glycosidase F (F-Gnase), to remove
all glycans, or endoglycosidase H, to remove only simple
glycans, showed that the hemichannel was complex glycosylated
and thus not retained within the endoplasmic reticulum
(Fig. 4A,B). A comparison of constitutive ethidium uptake in
the PANX1-HEKs versus WT HEKs showed that in the majority
of PANX1-HEKs there was no enhancement in the rate of dye
uptake compared to the untransfected cells, but that there was a
small population of PANX1-HEKs showing elevated ethidium
uptake (Fig. 4C), which might correspond to cells that have
higher levels of caspase activity. To further test the functionality
and pharmacology of PANX1 channels we measured dye uptake
in response to a hypotonic stimulus, previously shown to activate
these channels. There was a modest increase in rate but this was
not significantly reduced by carbenoxolone (CBX), a known
inhibitor of PANX1 (Fig. 4D). We next compared whole-cell
currents activated by hypotonic shock in WT and PANX1-HEK
cells. Hypotonic shock activated a strongly outwardly rectifying
current in the PANX1-HEKs that was of much larger amplitude
than the WT HEKs (Fig. 4E). This hypotonic-shock-induced
current was abolished by pretreatment with either CBX or the
10panx1 mimetic peptide (Fig. 4F,G). It was also inhibited by
transfecting siRNA targeted against hPANX1 into these cells
(Fig. 4H). Finally we co-expressed P2X7a receptors in the
PANX1-HEKs and this also significantly reduced the amplitude
of hypotonic-shock-induced outward currents, suggesting that the
receptor in its closed state exerts an inhibitory effect on PANX1
channel activation (Fig. 4I).
As a measure of colocalization between co-expressed P2X7
receptors and PANX1 channels we used an in situ proximity
ligation assay in combination with the anti-HA antibody, to
recognize PANX1–HA, and an anti-P2X7 C-terminal antibody.
The hPANX1 is 94% identical with the mouse isoform at the amino
acid level (Baranova et al., 2004). There was a strong positive
signal for P2X7 with PANX1, whereas neither P2X4 nor P2X2
expressed in these cells with their relevant antibodies gave any
signal to indicate proximity with PANX1 (supplementary material
Fig. S1A). Although P2X7 colocalized with PANX1, enhanced
expression of the hemi-channel did not affect surface trafficking of
Journal of Cell Science 125 (16)3780
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the receptor, as indicated either by the biotinylation and purification
of surface proteins or by the use of a membrane impermeable cross
linker BS3, which linked only subunits within receptors exposed at
the cell surface (supplementary material Fig. S1B).
Having shown enhanced expression of functional PANX1
channels in the stably transfected cells we compared ethidium
uptake triggered by P2X7aL451 and P2X7aP451 receptors in
both WT and PANX1-HEK cells in response to 300 mM BzATP.
For the P451 receptor the rate of ethidium uptake in WT and
PANX1-HEK cells was very similar, whereas for the L451
receptor the rate of uptake in WT cells was ,25% of the rate for
the P451 receptor, but this increased approximately threefold in
the PANX1-HEKs (Fig. 5A). To determine if sensitivity to
PANX1 expression is conferred by the L451 residue, we tested
ethidium uptake mediated by P2X7kL451 receptor in response to
100 mM BzATP. For this variant there was no significant
difference between WT and PANX1-HEK cells and the rate
was more than fourfold faster than for the P2X7aP451 receptor
(Fig. 5B). Similar experiments were performed but using a low-
dose of BzATP (10 mM and 30 mM) to partially activate
P2X7kL451 and P2X7aP451 receptors. Although the rates of
ethidium uptake were much slower, again there was no difference
between PANX1-HEKs and WT HEKs (Fig. 5C). Consistent
with these observations, CBX had no effect on the rate of dye
uptake mediated by either of these receptors in PANX1-HEKs,
indicating that the PANX1 channels were not involved in this
process. For the P2X7aL451 receptor, however, the increase in
ethidium uptake seen in the PANX1-HEKs was blocked by
treatment with either CBX or the 10panx1 inhibitory peptide
(Fig. 5D). Increased ethidium uptake is therefore mediated via
the overexpressed PANX1 channels. We also tested the effects of
an inhibitor of caspase-dependent apoptosis, zVAD-fmk, because
Fig. 3. Differential effects of NAD-dependent ADP
ribosylation on P2X7k and P2X7a receptor-
mediated responses. (A) The time course of NAD-
induced rise in cytosolic free Ca2+ in HEK cells co-
expressing P2X7aP451 or P2X7kP451 receptors with
ART2.2 measured by confocal microscopy using the
Ca2+-sensitive indicator Fura-Red. A decrease in
fluorescence indicates a rise in free [Ca2+]i. Cells were
incubated in 6 mM Fura-Red for 30 min at 37 C˚ prior to
imaging. (B) Whole-cell patch-clamp recordings from
cells expressing either P2X7kP or P2X7aP receptors
with ART2.2, in response to a 5 s application of NAD
or BzATP. P2X7a receptors did not respond to NAD.
The histogram summarizes the mean peak current
densities and shows the significant difference between
NAD- and BzATP-evoked responses (P,0.01, n55–8).
(C) Despite P2X7a receptors not responding to NAD,
prior application of NAD (5 s) reduced their response to
subsequent application of MgATP (3 mM, 5 s) in a
dose-dependent manner. There was a 10 s wash between
the NAD and the MgATP applications. Summary
histogram shows that the mean peak current density was
significantly reduced after a 5 s exposure to 300 mM
NAD (n54–7 cells; *P,0.01). Similarly, a 5 s
exposure to 30 mM NAD, reduced the response of
P2X7k receptors to a subsequent dose of MgATP
(n54–7 cells; *P,0.01). (D) The rate of ethidium
uptake mediated by P2X7aP and P2X7kP receptors in
response to 300 mM and 100 mM BzATP, respectively,
was also significantly reduced by the application of
300 mM NAD 20 s prior to the addition of BzATP.
P2X7a: n565–80 cells; *P,0.01. P2X7k: n565–85
cells; *P,0.01.
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caspase-dependent cleavage of PANX1 can directly activate the
channel and P2X7 receptor activation promotes apoptosis. Pre-
incubation with zVAD-fmk reduced P2X7aL451-mediated dye
uptake in the PANX1-HEKs to a level similar to that seen in the
presence of the PANX1 inhibitors. This suggests that signalling
between P2X7aL451 and PANX1 occurs downstream of the
activation of caspases. When we tested the effects of the PANX1
antagonists on receptor-mediated dye uptake in WT HEKs there
Fig. 4. Analysis of PANX1 channel function in HEK293 cells stably over-expressing the human isoform shows activation by hypotonic stimulus.
(A) hPANX1–HA was stably expressed in HEK cells (PANX1-HEK) and immunostaining with anti-HA antibody showed that the protein was expressed at the
plasma membrane. Scale bar: 10 mm. (B) Western blot using the anti-HA antibody of protein samples from PANX1-HEKs subjected to de-glycosylation
treatments shows that the majority of PANX1–HA protein was resistant to EndoH, indicating that it was complex glycosylated in the trans-Golgi network.
(C) Frequency histogram comparing constitutive ethidium uptake in WT and PANX1-HEK cells following incubation with ethidium bromide in isotonic NES for
10 min at room temperature. Dye uptake was enhanced in a small proportion (,20%) of the PANX1-HEKs (n5250–300 cells). (D) Co-expression of the P2X7aL
receptor in PANX1-HEKs did not affect the rate of constitutive ethidium uptake. There was, however, a small but significant increase in the rate of ethidium
uptake in hypotonic solution (n540–50; *P,0.05) and this was reduced in the presence of 100 mM carbenoxolone (CBX) but not significantly (n540–50;
P.0.05). (E) Whole-cell patch-clamp recordings from WT HEK cells and PANX1-HEKs showed that hypotonic shock induced a much larger strongly outward-
rectifying current in the PANX1-HEKs. The voltage was ramped between 280 mV and +80 mV. Hypotonic shock was applied by replacing the isotonic NES
(290 mOsml/l) with hypotonic NES (190 mOsml/l). The histogram shows the mean current amplitudes at 280 mV and +80 mV before and after hypotonic shock
(n56–8; *P,0.05). (F) Similar experiments were carried out to show that in the presence of 100 mM CBX, the hypotonic-shock-induced current in PANX1-HEKs
was dramatically reduced (n56; P,0.01). (G) Pre-incubation of PANX1-HEKs with 100 mM 10panx1 peptide for 15 min at 37 C˚, significantly reduced the
hypotonic-shock-induced current (n55; P,0.05). (H) Transfection of PANX1-HEKs with siRNA targeted against hPANX1 significantly reduced the hypotonic-
shock-induced response compared with scrambled siRNA (n54; P,0.01). (I) Co-expression of P2X7aL451 receptors in the PANX1-HEKs significantly reduced
the amplitude of hypotonic-shock-induced currents (n54; P,0.05).
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was no inhibition for either P2X7aL451 (Fig. 5E) or P2X7k
receptors (Fig. 5F). Dependency on PANX1 is thus restricted to
the condition in which the receptor with impaired ethidium
uptake (P2X7aL451) is co-expressed with the recombinant
PANX1 channels and the increase in dye uptake occurs over a
range of agonist concentrations (Fig. 5G).
Fig. 5. See next page for legend.
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Knockdown of PANX1 expression had no effect on
ethidium uptake mediated by P2X7a or P2X7k receptors
with P451
To further investigate coupling between PANX1 channels and the
P2X7 receptors we inhibited PANX1 expression using siRNA.
The efficiency of knockdown was tested in the PANX1-HEKs
where we could use the anti-HA antibody to compare expression
levels (Fig. 6A). In three separate experiments, western blot
analysis suggested that expression was reduced by between 50–
80%. Immunostaining also showed effective knockdown
following transfection with siRNA (Fig. 6B). Comparison of
ethidium uptake in WT HEK cells co-transfected with the
different P2X7 receptor variants and either PANX1 siRNA or
scrambled siRNA showed no difference in the rate of ethidium
uptake following PANX1 knockdown, consistent with the lack of
effect of CBX in these cells (Fig. 6C). In contrast, when PANX1-
HEKs were co-transfected with PANX1 siRNA and P2X7aL451
there was a significant reduction in the rate of dye uptake
compared to the scrambled siRNA condition (Fig. 6D). The
effect of the PANX1 siRNA was similar to the inhibitory effects
of CBX and zVAD–fmk and there was no additivity between
siRNA and CBX treatment and between zVAD–fmk and CBX,
consistent with them all acting by effectively abolishing PANX1
function.
Discussion
The comparison of the functional properties of the mouse P2X7a
and k receptors indicates that the k variant expressed in T-
lymphocytes is responsible for the NAD-dependent activation of
P2X7 receptors. Although both receptors are targets for ART2.2-
mediated ADP ribosylation, this modification is more efficacious
for the P2X7k variant and acts as a partial agonist of the receptor,
whereas at P2X7a it elicits no response. ADP ribosylation
permitted both the flux of small cations and the uptake of
ethidium mediated via the P2X7k receptor. The stabilization of
the active states of P2X7k compared to the P2X7a receptor is also
reflected in the increased potency of BzATP and insensitivity to
the P451L SNP. Despite the close proximity of coexpressed
P2X7 and PANX1 channels, P2X7 receptors mediate rapid
uptake of ethidium independently of PANX1 and only for the
P2X7aL451 receptor, which shows reduced uptake, did we
resolve a PANX1 component to ethidium uptake when the
hemichannel was overexpressed. This coupling was mediated
exclusively via caspase activation, rather than direct cross-talk
between the channels, as indicated by the inhibitory effects of
zVAD–fmk and the lack of any additivity when CBX was used in
combination with zVAD–fmk. These results show splice variants
of the rodent P2X7 receptor contributing to cell-type-dependent
diversity of P2X7 receptor function and provide evidence that
they can function as homo- and heteromers. They also suggest
that ethidium uptake, in addition to the transport of small cations,
is an intrinsic property of the receptor itself.
The restricted distribution of the P2X7k receptor
Previous analysis of the distribution of the P2X7k variant
indicated that it has a much more restricted expression than the
P2X7a variant (Nicke et al., 2009). Although the transcript for
P2X7k was identified in all of the wild type mouse tissue tested,
when we analyzed expression of the protein in the Glaxo
P2X72/2 mice, the only tissue with clear expression was the
spleen (Boumechache et al., 2009; Nicke et al., 2009). The ability
of the P2X7k receptor to escape inactivation in the Glaxo
P2X72/2 mice is because the disruption to the gene occurs in the
original exon 1 that is not utilized in the k variant. We were
unable to analyze expression of P2X7k protein in WT mice
because the antibodies available to us do not discriminate
between the two variants. The restricted distribution of P2X7k
receptors explains why the NAD sensitivity of endogenous P2X7
receptors has only been reported in T-lymphocytes.
ADP ribosylation acting as a partial agonist
Our finding that the P2X7a receptor co-expressed with ART2.2
in HEK cells is unresponsive to NAD even at high concentrations
has been shown previously (Adriouch et al., 2008). Gain-of-
function mutations were identified within the extracellular loop
of the receptor that promote NAD-dependent gating. They also
identified R125 as the target for ADP ribosylation and proposed
that the adenine nucleotide moiety fits into the ligand-binding
pocket of P2X7 between two adjacent subunits. Presumably this
modification would prevent the binding of soluble ATP within
the same pocket, which is consistent with our finding that NAD
can antagonize the actions of BzATP at the P2X7a receptor. The
identification of the P2X7k receptor as the mediator of the T-cell
NAD responses is important because this splice variant is
restricted to rodents and there is no human equivalent (Nicke
et al., 2009). In mice, NAD is an important physiological
regulator of T-cell P2X7 receptors because the concentration of
NAD required to activate these receptors is much lower than for
ATP; in the micromolar rather than the millimolar range. The
release of NAD by lytic and non-lytic mechanisms during
inflammation causes shedding of CD62L, PS flip and ultimately
cell death (Seman et al., 2003). Regulation of human T cells by
NAD is however likely to differ. Our prediction is that at the
hP2X7a receptor, NAD will have two actions: to antagonize the
effects of high doses of ATP, similar to what we have shown for
Fig. 5. P2X7aL451 receptor shows a pannexin-1-dependent component of
dye uptake but the other variants do not. (A) Representative time course of
300 mM BzATP-activated ethidium uptake for P2X7aL451 and P2X7aP451
receptors in WT HEK (WT) and PANX1-HEK cells (Pan). Summary
histogram compares the mean rate of increase in fluorescence between 15–35
s after application of BzATP and shows that uptake in PANX1-HEK
compared to WT cells was significantly greater for P2X7aL, but not for
P2X7aP receptors (n56, 60 cells per experiment; *P,0.01). (B) A similar
experiment, this time comparing dye uptake mediated by the P2X7kL
receptor with that of the P2X7aP receptor, shows the much faster rate for
P2X7kL and no affect of over-expression of PANX1. (C) The lack of
dependence on PANX1 for P2X7aP and P2X7k receptors was also seen at
lower doses of BzATP (10 mM and 30 mM for P2X7kL and P2X7aP,
respectively). Consistent with this there was no effect of 100 mM CBX on the
rate of ethidium uptake in PANX1-HEK cells. (D) For P2X7aL, the
potentiation of ethidium uptake in the PANX1-HEKs was abolished in the
presence of inhibitors, CBX (100 mM) and the 10panx1 peptide (100 mM).
Pre-incubation with zVAD-fmk (5 mM, 60 min at 37 C˚) also reduced
ethidium uptake in the PANX1-HEKs. The summary histogram is shown
below (n53, 60 cells per experiment; *P,0.05, comparing all conditions to
the PANX1-HEKs). (E) In contrast to the PANX1-HEKs, ethidium uptake
mediated by P2X7aL in WT HEK cells was insensitive to CBX and 10panx1
peptide. (F) Similar results were obtained for P2X7k receptors in WT HEKs.
(G) Concentration–response relationship for P2X7aL451 receptors activated
by BzATP in WT HEK cells and PANX1-HEK cells shows the increased rate
of ethidium uptake over a range of concentrations (PANX1-HEK cells:
EC50575 mM; WT HEK cells, EC505147 mM; n53, 60 cells per experiment).
Journal of Cell Science 125 (16)3784
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
mP2X7a receptors, but at low doses of ATP, to act
synergistically. Hong et al. showed that at mP2X7a receptors,
pre-stimulation with 100 mM NAD for 3–5 mins decreased the
threshold concentration of ATP required to activate a P2X7
receptor-mediated rise in [Ca2+]i (Hong et al., 2009). With at
least two ATP molecules required to bind to fully activate the
receptor an explanation for this result is that if a significant
proportion of receptors are only partially occupied with ATP,
Fig. 6. See next page for legend.
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then ADP ribosylation at the other site(s) might be sufficient to
promote activity. It is also possible that other variants of the
hP2X7 receptor are expressed in human T lymphocytes. Many
splice variants of the hP2X7 primary transcript have been
identified (Cheewatrakoolpong et al., 2005), the most prevalent
being the hP2X7b variant which has a very large deletion at the
C-terminus. This receptor has reduced function compared to the
hP2X7a receptor, does not trigger membrane permeabilization to
large molecules and thus seems an unlikely candidate for
mediating the effects of NAD (Adinolfi et al., 2010;
Cheewatrakoolpong et al., 2005). Also analysis of the
expression of mRNA for hP2X7b showed expression in
the spleen and T lymphocytes, but at a lower level than for the
P2X7a mRNA. Other variants of the hP2X7 receptor have been
shown to be non-functional (Feng et al., 2006b).
An intrinsic pathway for cation dye influx
The results of our experiments involving PANX1 overexpression
and knockdown are inconsistent with some previous studies,
which reported a crucial role for PANX1 in the P2X7 receptor-
mediated dye-uptake process in HEK cells (Iglesias et al., 2008;
Locovei et al., 2007; Pelegrin and Surprenant, 2006; Pelegrin
and Surprenant, 2009). Others, however, have also failed to
demonstrate an important role for PANX1 (Faria et al., 2005;
Schachter et al., 2008; Taylor et al., 2008). Our findings argue in
favour of the receptor itself forming an intrinsic pathway for the
influx of cationic dyes. One argument against an intrinsic
pathway for dye uptake is based upon the identification of a
proximal C-terminal region of P2X7 that appears to differentially
control permeability to NMDG+ and dyes (Jiang et al., 2005).
Deletion of this region of 18 amino acids (Y358–E375) in rat
P2X7 was reported to inhibit permeability to NMDG+ without
inhibiting receptor-mediated dye uptake suggesting the
involvement of two different pathways. A later study with
human P2X7, however, showed that this same deletion caused the
receptor to be instantaneously permeable to NMDG+ upon
opening rather than inhibiting permeability (Yan et al., 2008).
The ability to dissociate NMDG+ and dye permeation, does not,
however, provide conclusive evidence for the involvement of two
different proteins. If NMDG+ and ethidium do utilize a similar
pathway, then interactions between these cations and the receptor
are likely to differ and thus be differentially sensitive to site-
directed mutagenesis.
Functional coupling between P2X7 receptors and PANX1
Despite concluding that cationic dye uptake is intrinsic to the
receptor we were able to characterize a PANX1-dependent
component of receptor-mediated ethidium uptake, under
conditions where the intrinsic pathway was compromised by the
P451L substitution and PANX1 expression was high. Thus we
were able to demonstrate that signalling between P2X7 receptors
and PANX1 occurs downstream of the activation of caspases. Our
inability to resolve the PANX1 component under other conditions
is probably because it was considerably slower than the intrinsic
pathway. In some cellular context, however, the PANX1 pathway
might play a significant role in P2X7 receptor-mediated membrane
permeabilization, dependent upon the expression levels of the two
proteins, the duration and extent to which the receptor is activated
and the presence of interacting partners that might compromise
intrinsic dye uptake, as has been suggested for the interaction
between P2X7 receptor and non-muscle myosin IIA (Gu et al.,
2009). We also showed an inhibitory effect of P2X7 receptor
expression on hypotonic-shock-induced PANX1 activity,
consistent with functional coupling between the two channels,
and close proximity between P2X7 receptors and PANX1 when
they are co-expressed. This could help to ensure that PANX1-
mediated release of ATP promotes the activation of P2X7 in an
autocrine manner. In Jurkat T cells, PANX1-mediated ATP efflux
is triggered by apoptosis (Chekeni et al., 2010) and in erythrocytes
and retinal ganglion cells, PANX-mediated ATP efflux is triggered
by hypotonic stress (Bao et al., 2004; Locovei et al., 2006). The
autocrine action of ATP released from human T cells has been
shown to be an important mechanism for regulating endogenous
P2X7 responses. The activation of the T-cell receptor causes the
rapid release of ATP, which acts back upon the cells to stimulate
P2X7 receptors thereby triggering a rise in [Ca2+]i, NFAT
activation and interleukin-2 production (Yip et al., 2009). A role
for PANX1 in this process, however, has not yet been identified.
Materials and Methods
All reagents were purchased from Sigma Chemical Co. Ltd (UK) unless otherwise
stated. Culture media were supplied by GIBCO (UK). Endoglycosidase H (EndoH)
and N-glycosidase F (F-Gnase) kits were purchased from Roche (UK) and New
England Biolabs (UK), respectively, and used according to manufacturers’
instructions. Caspase family inhibitor, zVAD-fmk was purchased from
BioVision (USA). Mouse anti-V5 antibody was obtained from Invitrogen (UK).
Anti-HA mouse monoclonal antibody was obtained from COVANCE (USA) and
rabbit polyclonal P2X7 C-terminus (P2X7-CT), P2X2, and P2X4 antibodies from
Alomone (Israel). Anti-mouse and anti-rabbit HRP-conjugated secondary
antibodies were obtained from ThermoScientific (UK) and BioRad (UK),
respectively. The proximal ligation assay kit was from Olink Bioscience (UK).
The pannexin-1 mimetic peptide 10panx1 (WRQAAFVDSY) was synthesized by
Cambridge Bioscience (UK). siRNA duplexes were supplied by SigmaGenosys in
a powder form and were dissolved in RNase-free water. The solution was then
aliquoted and stored at 220 C˚ and used within 3 months. The anti-pannexin-1
siRNA (PANX1-siRNA) sequence (59-GCAUCAAAUCAGGGAUCCU-39) was
the same as that used previously (Pelegrin and Surprenant, 2006).
Drugs
All incubations with drugs were conducted at 37 C˚, 5% CO2 in a humidified
incubator unless otherwise stated. zVAD-fmk was used at a final concentration of
5 mM in DMEM with 60 min pre-incubation with the samples. The 10panx1
peptide was used at a final concentration of 100 mM in NES with 15 min pre-
incubation with the samples. Carbenoxolone (CBX) was used at a final
concentration of 100 mM in NES unless otherwise stated.
Fig. 6. Knock-down of PANX1 by siRNA had no effect on P2X7-
receptor-mediated ethidium uptake in WT HEKs but reduced uptake
mediated by P2X7aL451 receptors in PANX1 cells. Western blot (A) and
immunostaining (B) with the anti-HA antibody shows that transfection of
PANX1-siRNA markedly reduced the expression of PANX1 in HEK cells
stably overexpressing PANX1–HA (PANX1-HEK). Staining with anti-HA
used the Cy3 secondary antibody and pEGFP was co-transfected with the
PANX1-siRNA to identify transfected cells. In three individual western blot
experiments, expression of PANX1–HA was reduced by between 50 and 80%
following siRNA transfection. Scale bars: 10 mm. (C) The time courses of
BzATP-activated ethidium uptake in WT HEKs co-transfected with P2X7aL,
P2X7aP or P2X7kL, with either PANX1-siRNA or scrambled siRNA, shows
that there was no effect of PANX1 knockdown in the WT cells (n53). (D) In
contrast, BzATP-activated ethidium uptake for P2X7aLeu in PANX1-HEKs
was inhibited by co-transfecting PANX1-siRNA. The extent of inhibition was
very similar to pre-treatment with zVAD-fmk or CBX (n53; *P,0.05,
comparing all conditions to the scrambled siRNA treatment). There was no
additivity between PANX1-siRNA and CBX or between zVAD-fmk and
CBX indicating that all treatments effectively abolished PANX1 function.
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Animals
Spleen was obtained from adult C57 WT and Glaxo P2X72/2 (Sikora et al., 1999)
mice as described previously (Masin et al., 2012). All procedures were performed
with permission of the local Animal Health and Welfare Committees and in
accordance with the UK Home Office guidelines.
DNA constructs
P2X2, P2X4 and P2X7 were subcloned into the Clonetech GFP-N1 vector using
the NotI site to excise the coding sequence for GFP (Guo et al., 2007). hPANX1
bearing an HA tag (YPYDVPDYA) at the C-terminus was amplified using
the following sense and anti-sense primers: 59-AGCATAGAATTCGTCGCCA-
CCATGGCCATCGCTCAACTGGCC-39 and 59-TCTATGCGGCCGCTTATGC-
GTAGTCTGGCACGTCGTATGGGTAGCAAGAAGAATCCAGAAGTCTC-39.
P2X7a bearing an HA tag at the C-terminus was amplified using the following
sense and anti-sense primers: 59-AGCATAAAGCTTGTCGCCACCATGCCGGC-
TTGCTGCAGCTGG-39 and 59-GCGAACGCGGCCGCTCATGCGTAGTCTGG-
CACGTCGTATGGGTACTGAGCCACCATGATGTGGCAGC-39.
P2X7k bearing a V5 tag at the C-terminus was amplified using the following
sense and anti-sense primers: 59-AGCATAAAGCTTGTCGCCACCATGCTGCC-
CGTGAGCCACTTATG-39 and 59-GCGAACGCGGCCGCTCACGTGGAGTC-
GAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCTGAGCCACCATGA-
TGTGGCAGC-39.
All constructs were subcloned into the Clonetech GFP-N1 vector.
Cell culture
The HEK293 cells were maintained as described previously (Guo et al., 2007;
Moore and MacKenzie, 2007). They were routinely transfected using calcium
phosphate or Lipofectamine 2000 also as described previously (Guo et al., 2007).
Generation of stable PANX1-HEK cell line
HEK293 cells were seeded in six-well plates and 12–16 hours later, 60–70%
confluent cells were transfected with the plasmid encoding hPANX1 using calcium
phosphate. After 48 hours post-transfection, geneticin (G418), 0.8 mg/ml in fresh
medium, was added to the cells to select for transfected clones and the medium
was changed every other day. Once confluent, cells were transferred into flasks
and maintained in medium containing G418 (0.8 mg/ml) for a total of 4 weeks
from the transfection date.
siRNA transfection
siRNA was transfected into HEK293 cells using Lipofectamine 2000 (Invitrogen).
Briefly, 50–60% confluent cells seeded in 6-well plates were incubated in a fresh
antibiotic-free medium for at least 2 hours prior to transfection. siRNA (200 pmol)
and DNA (1 mg) were diluted in opti-MEM (200 ml) and incubated at room
temperature for 5 min. This was combined with Lipofectamine 2000 (6 ml) which
was also made up in 200 ml opti-MEM, and left for a further 20 min at room
temperature in the dark. The transfection mix was added dropwise to the cells
(400 ml/well). The cells were maintained at 37 C˚ and the medium was changed
24 hours later. Experiments were carried out 48 hours post-transfection.
Surface biotinylation, BS3 cross-linking and immunoblotting
Procedures were conducted as described previously (Boumechache et al., 2009).
Co-immunoprecipitation
Transfected cells were washed twice in ice-cold HBS supplemented with 2 mM
EDTA, harvested, and the membrane solubilised in HBS containing 1% Triton X-
100 for 1 hour at 4 C˚. The samples were subjected to ultracentrifugation at
50,000 g for 1 hour and incubated with pre-washed EZ View red anti-HA beads
(Sigma) at 4 C˚ for 3 hours. Protein–bead complexes were pelleted by
centrifugation, washed 3 times in 1 ml 1% Triton X solution, and the proteins
eluted from the beads using 100 mg/ml of the anti-HA antibody peptide before
analysis by SDS PAGE and western blotting.
Isolation of T cells
A homogenous population of T cells were obtained from spleen tissue of WT or
Glaxo P2X72/2 mice following the protocol described in Okkenhaug et al. with
slight modifications (Okkenhaug et al., 2006). Spleen tissue (WT and P2X72/2)
was disrupted and the cellular suspension was pooled and subjected to T-cell
isolation (,108 cells/tissue). Total T cells were isolated by negative selection
using FITC-conjugated anti-CD8, anti-CD69, anti-B220, anti-CD49b and anti-
MHC class II antibodies (BD or eBioscience), followed by immunoprecipitation
with anti-FITC MACS beads (Miltenyi Biotec), filtration and centrifugation.
Cellular pellets were resuspended and analyzed by SDS-PAGE followed by
western blot with anti-P2X7 antibody (Alomone).
Immunostaining
Immunostaining was carried out essentially as described previously (Guo et al., 2007).
In situ proximity ligation assay
In situ proximity ligation was carried out essentially as described previously using
the Duolink 1 kit (Olink Bioscience) (Antonio et al., 2011). HEK293 cells were co-
transfected with DNA encoding HA-tagged hPANX1 (hPANX1–HA) plus one of
the following rat P2X receptor subtypes: P2X7, P2X2 or P2X4, along with pEGFP
to identify transfected cells. The primary antibodies used were anti-HA, anti-
P2X7-CT, anti-P2X2 and anti-P2X4, all diluted 1:100 in FBS plus saponin.
Electrophysiology
Whole-cell patch clamp recordings were carried out as described previously (Qureshi
et al., 2007). The pipette solution was: 151 mM CsCl, 10 mM HEPES, 10 mM
EGTA, 3 mM MgCl2. Cells were maintained in normal extracellular solution (NES:
140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM D-glucose, 10 mM
HEPES, pH 7.3). Voltage ramps of 1 s duration between280 mV and +80 mV were
applied at 5 s intervals. Hypotonic shock was applied by exchanging the isotonic
NES (290 mOsml/l) with hypotonic NES (190 mOsml/l) made by diluting isotonic
NES with H2O. Pharmacological inhibitors of PANX1 currents were present in both
isotonic and hypotonic saline at the concentrations indicated.
Dye uptake
Cells on glass coverslips were mounted on a suitable chamber and maintained in either
NES or a low divalent NES (151 mM NaCl, 0.3 mM CaCl2, 10 mM D-glucose, 10
mM HEPES, pH 7.3). Experiments to generate concentration–response relationships
were performed in low divalent NES to improve the sensitivity of the measurements at
low agonist concentrations (Fig. 1; Fig. 2E; Fig. 5G), whereas all other experiments
were performed in NES as this contains more physiologically relevant levels of Ca2+,
which might affect downstream signalling pathways. Apart from the shift in sensitivity
to agonist there was essentially no difference in the results with either solution. The
chamber was placed on the stage of a confocal microscope and imaging was carried out
under 406oil immersion objective at room temperature. Ethidium bromide (20 mM in
NES), and BzATP were added to the cells at the specified time points in the presence or
absence of drugs. Ethidium was excited at 543 nm and the emission light was collected
at wavelengths $560 nm selected with a long-pass filter. The time course of dye
uptake was recorded using LSM510 software (Zeiss). For analysis, the nuclear region
for each cell was defined and the mean fluorescence intensity of the area was quantified
and plotted as a function of time. Rate of uptake was calculated using data collected
between 15 and 35 s after agonist application for BzATP-stimulated response and
between 30 and 100 s for NAD-stimulated response. The maximal amplitude was less
reliable because in some cells, highly expressing the receptor, there was some
saturation of the signal at the end of the experiment. When constructing the BzATP
concentration–response curves, the constitutive rate of dye uptake following the
addition of ethidium, was subtracted from the rate measured post BzATP application,
prior to normalization to the response to 100 mM BzATP at P2X7k, obtained on the
same day. Hypotonic-shock-induced dye uptake was measured by initially maintaining
cells in NES, applying ethidium bromide (20 mM) 25 s after starting the recording and
then applying a hypotonic shock by adding a volume of H2O to the cells that reduced
the osmolarity of the solution from 290 mOsml/l to 190 mOsml/l.
[Ca2+]i imaging
HEK cells expressing the P2X7a or P2X7k receptors were pre-incubated with
6 mM Fura-Red for 15 min at 37 C˚ in DMEM. The cells were then washed once in
NES and placed in a confocal chamber with NES. Cells were excited at 488 nm
and emission collected between 505–550 nm with a band-pass filter. Changes in
[Ca2+]i following agonist application were measured as a drop in fluorescence due
to the intracellular Fura-Red binding to free Ca2+.
Data analysis
Graphs were generated using Excel software (Microsoft) and statistical analysis
was performed using unpaired t-test. Where applicable, standard error mean
represented by error bars were indicated. Dose–response curves were generated
using Prism 5 and the non-linear regression curve fit equation.
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